NCT04573699 is a clinical trial of CNT-HF in Heart Failure NYHA Class II, sponsored by BackBeat Medical Inc.

Who is sponsoring NCT04573699?

NCT04573699 is sponsored by BackBeat Medical Inc.

What drugs are being tested in NCT04573699?

Interventions in NCT04573699: CNT-HF.

What condition does NCT04573699 study?

NCT04573699 studies Heart Failure NYHA Class II, Heart Failure NYHA Class III.

Is NCT04573699 still recruiting?

NCT04573699 is currently status unknown. Last updated 18 July 2022.

Last reviewed 2022-07-18 · How we verify

NCT04573699

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cardiac Neuromodulation for Heart Failure

Status unknown Last updated 18 July 2022

What this trial tests

trial testing CNT-HF in Heart Failure NYHA Class II in 11 participants. Status unknown.

Timeline

15 December 2020

Primary endpoint
31 January 2023

30 May 2023

Quick facts

Lead sponsor	BackBeat Medical Inc
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	11
Start date	15 December 2020
Primary completion	31 January 2023
Estimated completion	30 May 2023
Sites	1 location across Poland

Drugs / interventions tested

CNT-HF

Conditions studied

Heart Failure NYHA Class II — all drugs for Heart Failure NYHA Class II →
Heart Failure NYHA Class III — all drugs for Heart Failure NYHA Class III →

Sponsor

BackBeat Medical Inc — full company profile →

Who can join

18 and older, any sex, with Heart Failure NYHA Class II or Heart Failure NYHA Class III. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This investigation will evaluate the ability of the Moderato® System to safely and effectively deliver CNT, to reduce sympathetic activity in heart failure patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Heart Failure NYHA Class II

Currently open trials in the same condition.

NCT05632432 — Atrial Appendage Micrograft Transplants to Assist Heart Repair After Cardiac Surgery · NA · recruiting
NCT04829617 — Promoting Well-being and Health in Heart Failure · NA · recruiting
NCT03180320 — Baduanjin-eight-silken-movement With Self-efficacy Building for Patients With Chronic Heart Failure (BESMILE-HF Study) · NA · recruiting

Other BackBeat Medical Inc trials

Trials by the same sponsor.

NCT05719454 — Novel Setup Algorithm for Cardiac Neuromodulation Therapy · NA · recruiting
NCT05345925 — PV Loops With CNT in Multiple Pacing Sites · NA · unknown
NCT05086523 — Cardiac Neuromodulation Therapy (CNT) "Washout" Sub-Study · Phase 1, PHASE2 · unknown
NCT04463121 — Preload and Autonomic Responses With Cardiac Neuromodulation Therapy (CNT) (CS-06) · NA · unknown
NCT03757377 — Moderato System in Patients With Hypertension · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04573699 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by BackBeat Medical Inc
Last refreshed: 18 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04573699.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing